Pharma Stocks Slide Despite Double-Digit Growth📉

Despite double-digit revenue growth, these pharma companies' stock prices fall by 15%+. Could this be a hidden opportunity?🤔

1. Novo Nordisk $NOVO
-Revenue Growth: +26.2%
-Price Change: -21.4%
-ROE: +88.7%
-Free Cash Flow Margin: 18.3%
-Market Cap/Revenue: 9.45x

2. DexCom $DXCM
-Revenue Growth: +16.2%
-Price Change: -32.7%
-ROE: +32.1%
-Free Cash Flow Margin: 8.93%
-Market Cap/Revenue: 8.34x
#NOVO